key: cord-0950490-lovv0yoi
authors: Chin, I. S.; Galavotti, S.; Yip, K. P.; Curley, H.; Arnold, R.; Sharma-Oates, A.; Chegwidden, L.; Lee, S. I.; Lee, L. Y.; Pinato, D. J.; Dettorre, G. M.; Palles, C.
title: Influence of clinical characteristics and anti-cancer therapy on outcomes from SARS-CoV-2 infection: a systematic review and meta-analysis of 5,678 cancer patients
date: 2020-12-17
journal: nan
DOI: 10.1101/2020.12.15.20248195
sha: 8f0a34bebc9c7109f206d03a03705429ba3a5d6b
doc_id: 950490
cord_uid: lovv0yoi

Background The COVID-19 pandemic started a healthcare crisis and heavily impacted cancer services. Methods Data from cohort studies of COVID-19 cancer patients published up until October 23rd 2020 from PubMed, PubMed Central, medRxiv and Google Scholar were reviewed. Meta-analyses using the random effects model was performed to assess the risk of death in cancer patients with COVID-19. Results Our meta-analyses including up to 5,678 patients from 13 studies showed that the following were all statistically significant risk factors for death following SARS-CoV-2 infection in cancer patients: age of 65 and above, presence of co-morbidities, cardiovascular disease, chronic lung disease, diabetes and hypertension. There was no evidence that patients who had received cancer treatment within 60 days of their COVID-19 diagnosis were at a higher risk of death, including patients who had recent chemotherapy. Conclusions Cancer patients are susceptible to severe COVID-19, especially older patients and patients with co-morbidities who will require close monitoring. Our findings support the continued administration of anti-cancer therapy during the pandemic. The analysis of chemotherapy was powered at 70% to detect an effect size of 1.2 but all other anti-cancer treatments had lower power. Further studies are required to better estimate their impact on the outcome of cancer patients.

SARS-CoV-2 which has led to the COVID-19 pandemic has resulted in over 65 million COVID-19 cases and 1.5 million deaths globally as of 6 December 2020

[1][2] [3] . Cancer patients are considered to be at high risk from COVID-19 compared to the general population due to underlying immunosuppression from their malignancy and anti-cancer treatment. A large cohort study of over 20,000 hospitalised COVID-19 patients in the UK identified 1,743 (10%) patients with a cancer diagnosis, which was significantly associated with hospital mortality (adjusted HR 1.13, 95% CI 1.02-1. 24 , p=0.017) [4] . Cancer services was intentionally restricted in many countries at the beginning of the pandemic as a precaution. Since then, an estimated 20% increase in mortality in patients with new cancer diagnoses has been attributed to delays in diagnosis and treatment as a consequence of COVID- 19 [5] . A recent survey conducted by Cancer Research UK found that 1 in 3 cancer patients reported that their treatment had been affected by the pandemic [6] .

Balancing the benefits and risks of each patient's cancer treatment by taking into account factors such as treatment survival and response benefit, co-morbidities, prognosis, as well as the risks of immunosuppression are important considerations but often challenging [7] . We aimed to investigate the impact of cancer patients' characteristics, cancer type and recent treatment history on the risk of death in cancer patients following SARS-CoV-2 infection.

reporting on 10 or more COVID-19 positive cancer patients and provision of data on sex and age. For studies that had potentially overlapping participants based on the hospital recruitment sites and authors' institutions listed, the study with the largest number of participants was included. Studies that contained abstracts only or analysed specific cancer types only or paediatric cancers were excluded.

Two independent reviewers were allocated for each study. Counts of the number of patients that died and the number that recovered following SARS-CoV-2 infection, stratified by the following variables were extracted from each of the source data papers or requested from the corresponding author: sex, age, co-morbidities, Between-study heterogeneity was tested using the Sidik-Jonkman estimator.

Publication bias was assessed using funnel plots and funnel plot asymmetry was quantified with Egger's test if necessary. Power calculations for each analysis was performed using epiR(v1.0-15) package from 'R'.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 17, 2020. ; https://doi.org/10.1101/2020.12.15.20248195 doi: medRxiv preprint

15 papers published describing a total of 6,711 cancer patients with COVID-19 met the inclusion criteria. The number of COVID-19 cancer patients included in each study ranged from 25 to 1289 (Table 1) . The search and screening strategies used to identify each study is shown in Figure 1 and Table 1) .

Age and sex of COVID-19 cancer patients were reported in all the studies reviewed.

The pooled proportion of male COVID-19 positive cancer patients is 0.55 (95% confidence interval (CI) 0.51-0.60) with significant heterogeneity (I 2 81%, p<0.01) ( Supplementary Fig. 1) . A meta-analysis from 10 studies showed that male cancer patients had a higher risk of death compared to female cancer patients although this was not statistically significant (Risk Ratio(RR) 1.25, 95% CI 0.91-1.72, p-value=0.15) ( Supplementary Fig. 2 ). All studies reported either the median or mean age of COVID-19 positive cancer patients analysed, which ranged between age 52 to 76 and 55.3 to 71.6 respectively. Four studies showed a statistically significant . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 17, 2020. ; https://doi.org/10.1101/2020.12.15.20248195 doi: medRxiv preprint higher risk of death in patients who are of age 65 or older (RR 2.27, 95% CI 1.12-4.62, p=0.04), but with significant heterogeneity between studies (I 2 84.1%, p=0.0003) (Figure 2 ).

The outcomes of cancer patients with COVID-19 according to ECOG PS were reported in three studies. There was a non-significant higher risk of death in cancer patients with a PS of 3 or greater (RR 2.32, 95% CI 0.64-8.38, p=0.11) with considerable heterogeneity (I 2 73%, p=0.02) ( Supplementary Fig. 3 ). Four studies reported on outcomes for patients with and without a smoking history. On analysis, there was a non-significant association between smoking history and an increased risk of death (RR 1.37, 95% CI 0.76-2.49, p=0.19) ( Supplementary Fig. 4 ).

11 studies reported on the proportion of cancer patients with co-morbidities. Between 46% and 86% of the cancer patients in these studies had one or more co-morbidities (Supplementary Table 2 ). Meta-analysis from these studies showed a significant higher risk of death in patients with co-morbidities (RR 1.70, 95% CI 1.09-2.65, p=0.03) with significant inter-study heterogeneity (I 2 64.9%, p=0.004) (Figure 3a ). Six studies provided summary data on specific co-morbidities. Chronic lung disease, diabetes and hypertension were all significantly associated with higher risk of death (RR 2.12, 95% CI 1.33-3.39, p=0.009, RR 2.06, 95% CI 1.22-3.47, p=0.02 and RR 1.98, 95% CI 1.23-3.19, p=0.01 respectively) with heterogeneity only significant for hypertension scores (I 2 57%, p=0.04) (Figure 3b-d) . A meta-analysis of five studies showed that cardiovascular disease was significantly associated with an increased risk of death (RR 2.66, 95% CI 1.67-4.24, p=0.004) with also significant heterogeneity (I 2 68.7%, p=0.01) (Figure 3e ).

12 studies described the proportion of COVID-19 cancer patients with metastatic cancer. This ranged from 24.5% to 58.8% (Supplementary Table 2 ). A meta-analysis . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 17, 2020. ; https://doi.org/10.1101/2020.12.15.20248195 doi: medRxiv preprint of five studies showed that metastatic cancer was associated with a higher risk of death, but did not meet statistical significance (RR 1.53, 95% CI 0.98-2.37, p=0.06) ( Supplementary Fig. 5 ). However, three of the studies reported on all-cause mortality, while two studies reported COVID-19 related deaths. Therefore we were unable, in the former studies, to exclude the possibility that excess death risks could be attributed to cancer related deaths. 12 studies reported on the cancer types in their patient cohort. A meta-analysis of nine studies found a non-significant increased risk of death in haematological cancer patients (RR 1.34, 95% CI 0.91-1.99, p=0.12) (Figure 4a ). Four studies reported haematological cancers as the most frequent cancer type among patients with COVID-19. Meta-analysis of seven studies showed that gastrointestinal cancers were not significantly associated with an increased risk of death (RR 1.10, 95% CI 0.75-1.62, p=0.56) (Figure 4b ). Eight studies also showed no significant association between breast cancer and risk of death (RR 0.77, 95% CI 0.40-1.47, p=0.36) but there was significant heterogeneity (I 2 88%, P<0.0001) (Figure 4c) . Similarly, eight studies showed no significant association between death and thoracic cancers (RR 1.16, 95% CI 0.75-1.80, p=0.46) ( Figure 4d ). As the study by Lièvre only analysed solid cancers, we repeated the meta-analyses of gastrointestinal, breast and lung cancer without this study. The results were similar but remained non-significant (Supplementary Table 3 ).

12 studies provided information on cancer treatment history prior to COVID-19

infection. 10% to 65% of cancer patients received recent anti-cancer therapy prior to admission (Supplementary Table 2 ). The definition of recent treatment varied significantly between studies. A meta-analysis of six studies defining recent anticancer treatment as either receiving active treatment or within 60 days prior to infection showed a borderline significant reduction in the risk of death in those receiving anti-cancer treatment (RR 0.83, 95% CI 0.68-1.02, p=0.07) ( Supplementary Fig. 6a ). 11/13 studies had data on the types of anti-cancer therapy received. Chemotherapy was the most commonly administered in 9% to 37% of patients. A meta-analysis of seven studies demonstrated no significant association between recent chemotherapy and death (RR 1.04, 95% CI 0.88-1.24, p=0.59) ( Figure 5 ). In addition, six studies showed no significant association between recent . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 17, 2020. Fig. 6d & e) . Recent surgery was found to be associated with reduced risk of death with borderline significance (RR 0.79, 95% CI 0.63-0.99, p=0.047) from a meta-analysis of three studies ( Supplementary Fig. 6f ).

The funnel plot on the effects of co-morbidities appeared slightly asymmetrical, but no significant publication bias was detected based on Eggers' test (p-value=0.79).

Similarly, no apparent asymmetry was visualised in the funnel plots on the effects of recent chemotherapy or surgery ( Supplementary Fig. 7a -c).

This review and meta-analysis summarises the current data on patient characteristics and outcomes in cancer patients with COVID-19. To our knowledge, it includes the largest number of cancer patients and is the first to extract count data from all included studies . We also excluded studies that focused on specific cancer types in order to conduct an unbiased analysis of the risk of death associated with particular cancer diagnoses. In the case of studies that had recruited patients from the same geographical locations with overlapping authors' institutions, we took a conservative approach of only including one of these studies. Whilst we may have excluded more patients than necessary, we have ruled out including patients twice, which strengthens the quality of the research evidence generated. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 17, 2020. ; https://doi.org/10.1101/2020.12.15.20248195 doi: medRxiv preprint Consistent with previous meta-analyses of cancer patients by Liu and Zhang et al, we identified that age, male sex and the presence of co-morbidities were associated with an increased risk of death, although the meta-analysis of sex did not reach statistical significance [18] [19] . Large population studies of non-cancer COVID-19 patients have also found male patients, increasing age and chronic co-morbidities to be risk factors for increased hospital mortality [4] [20] . Our results also suggest ECOG PS of 3 or greater and presence of a smoking history as risk factors for increased death but these results were not significant. Assessment of ECOG PS is also poorly reproduced in retrospective studies and confounded by the rapid deterioration from acute SARS-CoV-2 infection in hospitalised patients.

Co-existent cardiovascular disease, chronic lung disease, hypertension and diabetes were all significantly associated with an increased risk of death in our analysis.

Significant between-study heterogeneity observed in the cardiovascular disease and hypertension meta-analyses were largely driven by the study by de Azambuja. This could partly be explained by the higher proportion of patients with cardiovascular disease (44%) than the other studies (6%-21%) [15] . Metastatic cancer patients with COVID-19 also appeared be at a higher risk of death. However, this analysis did not meet statistical significance and could be driven by confounding bias given that patients with higher cancer stages tend to have worse prognoses and not all studies in the meta-analysis reported on COVID-19 related deaths only.

Our meta-analyses also supported previous reports that patients with haematological cancers are at higher risk compared to patients with solid cancers [18] [21] . A high risk of death (34%) was also reported in a systematic review of over 3,000 haematological cancer patients [22] . Interestingly compared to the meta-analysis by is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 17, 2020. ; https://doi.org/10.1101/2020.12.15.20248195 doi: medRxiv preprint analysis does suggest that the impact of haematological cancer diagnosis may have been over-estimated by the smaller earlier studies whilst acknowledging the significant heterogeneity present (I 2 70%, p=0.001). Breast, gastrointestinal and lung cancers were common in the included studies, but we found no evidence of increased mortality risk within these cancer types. We did however find a high proportion of death among thoracic cancer patients from the included studies (37.7%), which supported the findings from a multi-centre study of 200 thoracic cancer patients that reported a high mortality rate of 33% in their cohort [23] .

A key question during this pandemic has been whether to delay or avoid cancer treatment during escalating viral transmission. There have been two previous metaanalyses that have focused on the effect of active or recent cancer treatment on outcomes [24] [25] . Yekedüz et al found no evidence of an association between recent anti-cancer treatment and increased risk of death when summary statistics from univariate models were analysed. However, they did find a statistically significant association between recent chemotherapy and an increased risk of death in multivariate models [25] . Park et al also found evidence of an association between recent chemotherapy and an increased risk of death when analysing summary statistics from univariate and multivariate models [24] . The multivariate analysis by 

Our analyses had several limitations. We were only able to include a limited number of studies in the meta-analyses for age, ECOG PS, smoking status, recent surgery, radiotherapy and hormonal therapy due to the lack of summary statistics from other studies for these variables. Statistical power to detect moderate effects (RRs) between 1.2 and 1.5 was low for the analyses of the impact of the different anticancer therapies on mortality. We were also unable to conduct further meta-analyses of odds ratios as most of the studies had adjusted their reported results for different variables. In addition, our review did not cover the rates and outcomes of haematological cancer patients who received either bone marrow or stem cell transplant or immunomodulatory medication due to the lack of data available for these therapies. Therefore, there is a need for further studies to evaluate the risks of patients receiving these therapies.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 17, 2020. ;

Our meta-analysis of up to 5,678 patients has identified older age and presence of co-morbidities including cardiovascular, chronic lung conditions, diabetes and hypertension as significant risk factors among cancer patients with COVID-19.

There was no clear increase in risk of death for a particular cancer type, although there was a trend towards haematological cancers being at higher risk compared to solid cancers. There was also no increase in risk of death with any recent anticancer therapy, including chemotherapy. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 17, 2020. ;

in Reggio Emilia. Biology (Basel) 2020;9:181. https://doi.org/10.3390/biology9080181. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 17, 2020. ; e . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis

Clinical determinants for fatality of 44,672 patients with COVID-19

A systematic review and meta-analysis of cancer patients affected by a novel coronavirus

Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data

A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19

Delaying surgery for patients with a previous SARS-CoV-2 infection

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Mortality in Cancer Patients: A Report from a Tertiary Cancer Centre in India

Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

COVID-19 in Cancer Patients From New York City: A Comparative Single Center Retrospective Analysis

Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London

Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute

Systematic investigations of COVID-19 in 283 cancer patients